Cyclerion Therapeutics, Inc. - 10-Q Filing
Cyclerion Therapeutics filed its Q1 2026 10-Q report, disclosing ongoing operations as a pre-revenue biopharmaceutical company focused on drug development. The filing highlights the pending merger with Korsana Biosciences Inc., subject to stockholder approval and completion of financing by April 1, 2026. It also outlines financial constraints, including uncertainties around continued operations due to substantial doubt about its ability to remain a going concern.
Tickers: $CYCN